Urate-lowering therapy for gout: Focus on febuxostat

Pharmacotherapy

Volumn 30, Issue 6, 2010, Pages 594-608

  Love, Bryan L ^a   Barrons, Robert ^a   Veverka, Angie ^a   Snider, K Matthew ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

Allopurinol; Febuxostat; Gout; Gouty arthritis; Hyperuricemia; Uric acid

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; AZATHIOPRINE; BENZBROMARONE; COLCHICINE; CORTICOSTEROID; DIDANOSINE; FEBUXOSTAT; IBUPROFEN; INDOMETACIN; MERCAPTOPURINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PLACEBO; PROBENECID; SULFINPYRAZONE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; URATE; URIC ACID; URIC ACID DERIVATIVE; URICOLYTIC AGENT; URICOSURIC AGENT; WARFARIN;

ARTHRALGIA; BLEEDING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE CLEARANCE; DERMATITIS; DIARRHEA; DIZZINESS; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; FEVER; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GOUT; HEART INFARCTION; HUMAN; HYPERURICEMIA; HYPOURICEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; MAXIMUM TOLERATED DOSE; NAUSEA; PAIN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PEPTIC ULCER; REBOUND GOUT ATTACK; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEX DIFFERENCE; SHORT COURSE THERAPY; SIDE EFFECT; STOMACH HEMORRHAGE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MODELS, BIOLOGICAL; THIAZOLES; XANTHINE OXIDASE;

EID: 77952899115     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.6.594     Document Type: Review

References (60)

1. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol 2002;29:2403-2406
2. Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum 1995;38:628-632
3. Wallace KI, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-1587 (Pubitemid 39006641)
4. Hootman JM, Helmick CG, Schappert SM. Magnitude and characteristics of arthritis and other rheumatic conditions on ambulatory medical care visits, United States, 1997. Arthritis Rheum 2002;47:571-581
5. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005;165:742-748 (Pubitemid 40569426)
6. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003; 349:1647-1655
7. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324-1328
8. Kim KY, Schumacher HR, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-1617 (Pubitemid 36805619)
9. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987;82:421-426
10. McCarty DJ. Gout without hyperuricemia. JAMA 1994;271:302-303
11. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-1311 (Pubitemid 44641591)
12. Nesher G, Moore TL. Clinical presentation and treatment of arthritis in the aged. Clin Geriatr Med 1994;10:659-675 (Pubitemid 24359003)
13. Wazir NN, Moorthy V, Amalourde A, Lim HH. Tophaceous gout causing atlanto-axial subluxation mimicking rheumatoid arthritis: a case report. J Orthop Surg (Hong Kong) 2005;13:203-206
14. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
15. Coe FL, Moran E, Kavalich AG. The contribution of dietary purine over-consumption to hyperpuricosuria in calcium oxalate stone formers. J Chronic Dis 1976;29:793-800. (Pubitemid 8020088)
16. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-1103 (Pubitemid 38298989)
17. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363:1277-1281 (Pubitemid 38496489)
18. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-1324 (Pubitemid 44620440)
19. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-1374
20. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007;120:442-447 (Pubitemid 46656248)
21. Ebrahimpour P, Fakhrzadeh H, Heshmat R, Bandarian F, Larijani B. Serum uric acid levels and risk of metabolic syndrome in healthy adults. Endocr Pract 2008;14:298-304.
22. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-2696 (Pubitemid 44208638)
23. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104-1110 (Pubitemid 351749228)
24. Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009;53:796-803.
25. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-2416 (Pubitemid 39480701)
26. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-1860 (Pubitemid 351736009)
27. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008;(2):CD005521.
28. Rott KT, Agudelo CA. Gout. JAMA 2003;289:2857-2860
29. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995;22:908-914
30. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005;17:319-324 (Pubitemid 40616579)
31. Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol 2007;19:122-127
32. Stamp LK, O'Donnell JL, Chapman PT. Emerging therapies in the long-term management of hyperuricaemia and gout. Intern Med J 2007;37:258-266 (Pubitemid 46457505)
33. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-934 (Pubitemid 43993484)
34. Sanofi-Aventis U.S., LLC. Elitek (rasburicase) package insert. Bridgewater, NJ; 2008.
35. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005;20:431-433 (Pubitemid 40276903)
36. Chohan S, Becker MA. Update on emerging urate-lowering therapies. Curr Opin Rheumatol 2009;21:143-149
37. Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008;49:384-387
38. Okamoto K, Nishino T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. J Nippon Med Sch 2008;75:2-3. (Pubitemid 351303851)
39. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76:1835-1847 (Pubitemid 40215224)
40. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleos Nucleot Nucleic Acids 2004;23:1111-1116 (Pubitemid 39625877)
41. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 2006;45:821-841 (Pubitemid 44192308)
42. Ipsen, Inc. Adenuric (febuxostat) package insert. Paris, France; 2009.
43. Takeda Pharmaceuticals America, Inc. Uloric (febuxostat) package insert. Deerfield, IL; 2009.
44. Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2006;46:88-102. (Pubitemid 43021717)
45. Komoriya K, Hoshide S, Takeda K, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleos Nucleot Nucleic Acids 2004;23:1119-1122 (Pubitemid 39625879)
46. Hoshide S, Takahashi Y, Ishikawa T, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleos Nucleot Nucleic Acids 2004;23:1117-1118 (Pubitemid 39625878)
47. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005;12:22-34. (Pubitemid 40516043)
48. Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008;48:1014-1024
49. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-923
50. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-2461
51. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-1548
52. U.S. National Institutes of Health. Efficacy and safety of oral febuxostat in subjects with gout (CONFIRMS). Available from http:// clinicaltrials.gov/ct2/show/ NCT00430248?term=febuxostat&rank=3. Accessed October 13, 2009.
53. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009;48:188-194
54. Becker MA, Schumacher HR, Macdonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-1282
55. Bristol Myers Squibb. Videx EC (didanosine) package insert. Princeton, NJ; 2008.
56. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996;30:951-954
57. Manfredi RL, Vesell ES. Inhibition of theophylline metabolism by long-term allopurinol administration. Clin Pharmacol Ther 1981;29:224-229 (Pubitemid 11139900)
58. Khosravan R, Grabowski B, Wu JT, Joseph-Ridge N, Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol 2008;65:355-363 (Pubitemid 351316909)
59. Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 2008;38:496-510.
60. Khosravan R, Wu JT, Joseph-Ridge N, Vernillet L. Pharmaco-kinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol 2006;46:855-866 (Pubitemid 44050822)